Aradigm doses first patient in Phase III trial of ciprofloxacin to treat non-cystic fibrosis bronchiectasis
"I am pleased that our team has achieved this very important milestone, which also further strengthens our financial position," said Nancy Pecota, Chief Financial Officer, Aradigm. The Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.